NCT04811950

Brief Summary

The biological rationale in calculating PLR stems from the increase in the lymphocyte count and reduction in the platelet count often encountered in the advances stages of CLL .NMR median value was significantly higher in untreated patients than in patients who received treatment strengthening the hypothesis that this ratio is associated with a more indolent form of disease

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2019

Completed
1.5 years until next milestone

First Posted

Study publicly available on registry

March 23, 2021

Completed
1.2 years until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2023

Completed
Last Updated

March 23, 2021

Status Verified

March 1, 2021

Enrollment Period

3 months

First QC Date

September 30, 2019

Last Update Submit

March 22, 2021

Conditions

CLL Progression

Outcome Measures

Primary Outcomes (1)

  • platelet-lymphocyte and neutrophilo_monocyte ratio in CLL

    Calculating the ratio of platelets to lymphocytes and neutrophils to monocytes in CLL cases

    base line

Interventions

EmeraldDEVICE

Complete blood countdevice

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All Patients with CLL come to South Egypt Cancer institute from 2010 to 2020

You may qualify if:

  • \- All CLL patients

You may not qualify if:

  • CLL patients on treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Yu H, Xu W, Shen QD. [Serum levels of soluble CD(23) and thrombopoietin in chronic lymphocytic leukemia]. Zhonghua Nei Ke Za Zhi. 2008 Oct;47(10):826-9. Chinese.

    PMID: 19080142BACKGROUND

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

September 30, 2019

First Posted

March 23, 2021

Study Start

June 1, 2022

Primary Completion

September 1, 2022

Study Completion

October 1, 2023

Last Updated

March 23, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share